Background. General practitioners (GPs) will face cancer recurrences more frequently due to the rising number of cancer survivors and greater involvement of GPs in the follow-up care. Currently, GPs are uncertain about managing recurrence risks and may need more guidance.
Introduction
The number of cancer survivors is rising as a result of the increasing incidence of cancer and the advances in treatment and early detection (1, 2) . In 2012, there were almost 32.5 million cancer survivors worldwide (3) . The World Cancer Research Fund estimates that this number will grow to almost 70 million survivors in 2050 (4) .
On completion of curative cancer treatment, patients usually receive follow-up care in secondary care settings by medical specialists (5, 6) . Due to the rising number of cancer survivors, the limited capacity of secondary care facilities to provide follow-up care, and the increasing costs, general practitioners (GPs) are increasingly involved in the follow-up care (7) (8) (9) . An important component of follow-up care is detecting recurrence (5) .
Recurrences regularly occur between scheduled follow-up visits and are often initially presented as symptoms to the GP (10) (11) (12) . In addition, recurrences that occur many years after the initial treatment are probably also first presented to the GP.
It is expected that GPs will face cancer recurrences more frequently in particular, in follow-up care of common tumour types with high survival rates and with recurrences occurring many years after treatment, such as breast cancer, colorectal cancer and melanoma (13) (14) (15) . It is important that GPs are able to detect recurrence and refer patients in time to secondary care for treatment.
In order to provide optimal recurrence risk management, GPs need more applicable guidance (16) (17) (18) (19) (20) (21) (22) . GPs are especially uncertain about the type and, frequency of tests, and the length of maintaining a test scheme during the follow-up (21) . Besides, GPs expect that providing this care increases their workload (23) (24) (25) and that they need more expertise and formal training (16, (23) (24) (25) (26) (27) . A recent study on evidence-based recommendations on care for breast cancer survivors in five recent evidence-based guidelines showed that these guidelines are insufficiently helpful for GPs (28) . This stimulates the need of including guidelines not evidence based.
To uncover what guidance is available for GPs on managing recurrence risks in patients with breast cancer, colorectal cancer and melanoma, and to examine whether recurrence risk management differs between these tumour types, we made an inventory of existing clinical practice guidelines originating from Australia, Canada, European countries, New Zealand and USA and created an overview of presented guidance.
Methods
Two strategies were used to collect guidelines. As part of the European Union Joint Action Cancer Control (CanCon; www.cancercontrol. eu), a Joint Action (29) which aims to contribute to reducing the cancer burden in the European Union, an inventory of existing clinical practice guidelines in European countries via national experts was undertaken and in addition internet and scientific literature was searched to complete the inventory of guidelines.
Inventory of guidelines via experts
In Autumn 2014, experts from the European Union Member States and four other non-EU countries (Norway, Switzerland, Iceland and Turkey) were asked to supply existing national and/or regional guidelines from their own country. Experts were delegates from national primary care associations, nursing associations, universities with a medical department and CanCon associated partners. At least three experts per country were approached. In December 2014, also delegates were approached from the Cancer and Primary Care
Research International Network (CA-PRI), the European Forum for Primary Care (EFPC), the European Society of General Practice/Family Medicine (WONCA Europe) and CanCon collaborating partners from nonresponding countries. Inclusion criteria were that guidelines needed to contain guidance on care for adult cancer survivors, subsequent to curative treatment, and that they were (potentially) relevant to GPs.
Internet and literature search
A bibliographical database search using the terms 'guideline', 'breast cancer', 'colorectal cancer', 'colon cancer', 'rectum cancer', 'melanoma' was conducted in January 2015 to complete the inventory of clinical practice guidelines. Databases included Embase and Medline. Also, the National Guideline Clearinghouse website, the Guidelines International Network (G-I-N) website and cancer agency websites were searched for relevant tumour-specific guidelines (see Supplementary Table 1 for all websites that were searched). Guidelines with a publication date from 2000 to 2015 were included and searches were conducted without any language restriction. Guidelines were required to contain guidance on care for cancer survivors that was (potentially) relevant to GPs, subsequent to curative treatment.
Guideline selection
Guidelines obtained from literature and internet searches were selected on basis of title. Screening of guidelines was done by one researcher (IS). We included guidelines focusing on adults and originating from western countries, as mentioned above, and Australia, Canada, New Zealand and USA. We excluded older versions of guidelines, duplicates, those that were specifically made for oncologists, and those that only focussed on early detection, screening, treatment or palliative care, advanced cancer or metastasis, or on specific patients groups, e.g. hereditary cancer survivors and childhood cancer survivors.
Data extraction and content analysis
Data were extracted on the target audience of the guideline, the clinical content and the supporting evidence. Evidence was defined as one or more references to scientific, peer reviewed sources. Translations were used for data extraction from guidelines written in other languages than English or Dutch. The data from Croatian, Danish, Finnish, Norwegian and Polish guidelines were validated by the expert who provided the guidelines. Translations of data from the French, German and Italian guidelines were validated by researchers from the NIVEL institute who were native speakers or who speak the specific language. Extracted data were categorized into 'guidance on recurrence risk management' and 'other guidance' by two researchers independently (IS and JK). Subsequently, it was assessed whether the recommendations were relevant for GPs; recommendations on diagnostic tests performed in a secondary care setting were excluded.
Based on the relevant guidance, a clinical topic list for each tumour type was composed. The topic lists were composed by one researcher (IS) and checked by a second researcher (JK). Guidance was independently allocated to topics by two researchers (IS and JK). If guidance did not fit into the predefined topics, a new topic was created by discussion. Disagreements on categorization or allocation into topics were resolved by discussion with a third researcher (FS).
Results

Included guidelines
Twelve countries indicated that there were no tumour-specific guidelines containing information on care for cancer survivors (potentially) relevant for GPs. From other countries, we received at least one tumour-specific guideline on breast cancer (n = 16), colorectal cancer (n = 17) or melanoma (n = 13). Thirty of these guidelines were considered eligible and were included. Excluded guidelines were duplicates (n = 3), translated versions of included guidelines (n = 3) and guidelines specifically targeting oncologists (n = 10) (Fig. 1) .
The database search yielded 639 results, the National Guideline Clearinghouse website 547 results and the G-I-N website 246. In total, in the databases and on the cancer agency websites, 30 additional relevant guidelines were found. Overall, 60 guidelines were deemed eligible, including 24 breast cancer guidelines, 21 colorectal cancer guidelines and 15 melanoma guidelines (Supplementary Table 2 ). The colon cancer and rectal cancer guideline from the United States included the same guidance, therefore only the colon cancer guideline was used. Included guidelines were published between 2003 and 2015 and originated from Europe (n = 45), Canada (n = 7), United States (n = 5) and Australia and New Zealand (n = 3). Twenty-eight guidelines were not published in English: five were published in Dutch, five in German, three in Danish, three in Finnish, three in French, three in Polish, two in Croatian, two in Italian and two in Norwegian. Three guidelines were specifically made for GPs (30, 31) and three guidelines provided a summarized guide explicitly for GPs (32) (33) (34) . Furthermore, 23 other guidelines mentioned the GP explicitly as part of their target audience.
Identification of topics
Eight topics were identified in the breast cancer and melanoma guidelines (Fig. 2) . In colorectal guidelines, seven of these topics were covered; self-examination was not mentioned. For all tumour types, most attention was given to recurrence detection by recommendations on diagnostic testing. Physical examination was recommended for each of the three tumour types. Self-examination by patients was recommended in 87% of the melanoma and in 29% of the breast cancer guidelines. Additional, diagnostic imaging (mammography) for breast cancer and laboratory diagnostic testing [carcinoembryonic antigen testing (CEA)] for colorectal cancer was recommended. Another topic that was often highlighted was awareness of cancer recurrence; it was mentioned in 67% of the breast cancer, 73% of the melanoma and 80% of the colorectal cancer guidelines. In contrast, specific signs and symptoms of recurrence received limited attention; these were reported in 15% of the colorectal cancer, 21% of the breast cancer and 33% of the melanoma guidelines. Differences in coverage of topics between guidelines from the tumour types were also observed. Risk of recurrence/second cancer was pointed out in most breast cancer (67%) and melanoma guidelines (73%), but in less colorectal cancer guidelines (40%). Recommendations on organization of care were provided in 67% of the breast cancer guidelines, in 50% of the colorectal cancer guidelines and in 33% of the melanoma guidelines.
Recommendations on frequency of diagnostic testing
Breast cancer
Recommendations on the frequency of physical examination were provided in 20 out of 24 guidelines and all 24 guidelines reported a recommended frequency of mammography (Table 1 ). Broad consensus existed on annual mammography. Additionally, 10 guidelines stated that the first mammogram after breast conserving therapy should take place after at least 6 months. Less agreement was observed on the frequency of physical examination ranging from one to four times a year in the first 3 years after treatment. In the 3 subsequent years, most guidelines recommended (semi-) annually examinations. Guidelines agreed on an annual examination after 3 years.
Colorectal cancer
Eighteen out of 20 guidelines contained recommendations on time intervals between consecutive physical examinations and nineteen on time intervals between consecutive CEA testing. Eleven guidelines recommended the same frequency for both tests. Overall, there was some agreement among guidelines on the time intervals between consecutive tests. Recommended time intervals were 3-to 6-monthly in the first 3 years and 6-to 12-monthly in the 4th and 5th year ( Table 2 ). All, except one guideline, agreed that there is no need for diagnostic testing after 5 years.
Melanoma
Guidance on time intervals between consecutive physical examinations was provided by 12 out of 15 melanoma guidelines, two other guidelines stated that the frequency and the duration of follow-up should be tailored to each individual patient. Recommended time intervals in eight guidelines were dependent on the stage of the melanoma as the risk of recurrence/second cancer is related to the primary tumour thickness (35) . Recommendations were inconsistent on the time intervals between consecutive tests for both stage I and stages II and III, ranging from one to four times a year in the first 5 years after treatment ( Table 3 ). Most guidelines (67%) stressed that the more advanced the disease the shorter the time intervals should be in the first 2 years. Most guidelines (83%) agreed on continuing testing during 5 to 10 years after the initial treatment. After 10 years, there was disagreement whether to stop or continue testing.
Evidence regarding recurrence risk management
Eighteen out of 59 reviewed guidelines did not include any references to scientific evidence related to cancer recurrence risk management.
Among the guidelines that included references, the range in the number of references was one to 54. Only few guidelines provided evidence-based recommendations on time intervals; five on physical examination and ten on mammography for breast cancer, three on both physical examination and CEA testing for colorectal cancer and five on physical examination for melanoma. Evidence-based recommendations showed the same discrepancies in preferred time intervals as the recommendations were not evidence based (data not shown).
Discussion
This is the first inventory evaluating guidance on recurrence risk management available in existing breast cancer, colorectal cancer and melanoma guidelines that is (potentially) relevant to GPs. It demonstrates that the topics on recurrence risk management were rather similar among the three tumour types and that few guidance on recurrence risk management is targeted to GPs. Most attention was given to recurrence detection often by highlighting the importance of the diagnostic tests. For each tumour type, there is consensus among the guidelines about the preferred type of diagnostic tests, but, recommended frequencies for follow-up are inconsistent, except for mammography screening for breast cancer, reflecting the lack of evidence in this field.
The guidance on recurrence risk management of three tumour types could be summarized into identical topics with similar components. This facilitates GPs to provide follow-up care because the same pattern applies for different tumour types. However, GPs still need more knowledge on details, like on diagnostic tests, which are specific per tumour type.
Overall, the main focus in the guidelines is recurrence detection through consecutive diagnostic testing. Guidelines agree on both routine and nonroutine tests, but, except for mammography screening for breast cancer, recommendations on time intervals are inconsistent. This diversity reflects the lack of high quality evidence available; recommendations are mainly based on expert opinion. Although, the evidence-based recommendations showed the same discrepancies in preferred time interval. Thus the lack of agreement not only arises from expert opinions. The discrepancies in recommended time intervals make it difficult for GPs to determine the frequency of followup. This problem was confirmed by a study investigating the views of GPs on follow-up care (21) . Most common problems among GPs were uncertainty about the type and frequency of diagnostic tests and duration of follow-up. Even when guidance is univocal and evidence based, its implementation is crucial to improve the quality of care and, subsequently, the survival of cancer. Further research is needed to examine the facilitators and barriers of implementing 1st year  6  7  5  ---8  6  5  ---2nd year  5  7  6  ---7  6  6  ---3rd year  2  5  10  --1  4  5  9  --1   4th year  --10  3  4  1  --10  3  2  4   5th year  --10  3  4  1  --10  3  2  4   >5 year  ----1  17  -----19 18 of the 20 guidelines reported time recommended intervals on physical examination and 19 guidelines on carcinoembryonic antigen testing. The enclosed cells contain the highest number of guidelines recommending a specific time interval. the guidance on recurrence risk management in daily practice and whether this leads to better cancer survival in respective countries.
Awareness of cancer recurrence is also often mentioned in the guidelines. However, specific signs and symptoms that may indicate recurrence are reported by few guidelines and only one guideline provided EB guidance on signs of recurrence (33) . Signs of recurrence also receive little attention in the scientific literature as there is a paucity of research in this field, especially in the primary care setting. Until now, only one study examined the signs of recurrence in primary care (36) . This study showed that the symptoms of recurrence in primary care were very different from those reported by secondary care, reflecting the need for specific guidance on signs of recurrence for primary care. More research in primary care is needed to fill the knowledge gap.
Most melanoma and breast cancer guidelines report the risk of recurrence and state which patients have an increased risk of recurrence, but only few colorectal cancer guidelines discuss this, although the risk of recurrence is not significantly lower in colorectal cancer (37) (38) (39) (40) . In addition to detection of recurrence by health care providers, recurrences are also detected by the patients themselves (41, 42) . Almost all melanoma guidelines provide instructions on self-examination to patients, whereas only 29% of the breast cancer guidelines recommend this. This is in accordance with the current literature; regular self-examination does not reduce breast cancer morbidity or mortality and it is associated with an increased number of physician visits and high rates of benign biopsies (43) (44) (45) . For melanoma, self-examination is promoted (46, 47) as evidence suggests that self-examination is associated with reduced mortality (48) and the vast majority of melanomas and melanoma recurrences are found by patients themselves (41, 49, 50) . Besides, melanomas found by self-examination have been shown to be thinner than those found incidentally (51) .
A previous study from our group focussing just on evidencebased recommendations on care for cancer survivors in five recent evidence-based breast cancer guidelines showed that these guidelines are not helpful to GPs (28) . We used the same method as in the current study and restricted the inclusion to evidence-based guidelines and identified the same topics, except for signs of recurrence. Signs of recurrence were never covered by the evidence-based recommendations. Recommendations on the frequency of mammography screening were the same as in the current study, but, in contrast to the lack of agreement on the recommended frequency of physical examination in the current study, the evidence-based recommendations agreed on the frequency of physical examination. However, a limitation was that only two guidelines provided a recommendation on physical examination and three on mammography. This limited number of evidence-based guidelines stimulated the need to include guidelines not evidence-based as is done in the current study.
All guidelines in our study included both evidence-based recommendations as well as opinion based recommendations. The lack of clear and uniform data to support recommendations calls for expert opinions, which could explain differences between the guidelines. However, we also found discrepancies between evidence-based recommendations, showing the influence of interpretation of research findings is not always straightforward.
Our study showed limited applicability of cancer guidelines for GPs, which was also highlighted by an earlier study focussing on breast cancer, colorectal cancer and prostate cancer guidelines (19) . Another recent publication focussing on the role of the GP in aftercare, also found that recommendations in guidelines are often not targeted toward GPs (52) . Involvement of GPs in the development of guidelines could raise the number and relevance of recommendations to GPs (19) . However, it may be argued whether this is sufficient. Due to the limited applicability of current guidelines for GPs, it seems the right time to develop GP specific guidelines. These could address specific topics that are relevant in the GP care setting, where care is more holistic and includes personalised care for patients' comorbidities. A first example that a GP guideline is feasible, is a recent guideline on care for breast cancer survivors as developed in the United Stated (53) . This guideline is, where possible, based on research in primary care.
A strength of this inventory is the input of 45 experts from all 32 approached countries. We gained information from all European Union countries and collected additional information from other Western countries. Therefore, we were able to create a fairly complete overview of guidance on recurrence risk management for GPs.
A limitation of present study is the inclusion of guidelines older than 5 years. It is has been demonstrated that almost half of the guidelines are outdated after 5 years (54) . Although, no differences were seen in both included topics and guidance between the older and newer guidelines. This might indicate a low availability of new evidence on recurrence risk management in the recent years. 
Conclusion
This inventory represents the guidance on recurrence risk management (potentially) relevant for GPs provided in breast cancer, colorectal cancer and melanoma guidelines. It shows that care on recurrence risk management has overlapping areas between tumour types, making it more feasible for GPs to provide this care. However, only little guidance on recurrence risk management is specific for GPs and recommendations between time intervals of consecutive diagnostic tests are inconsistent, making it hard for GPs to know how to manage recurrence risks and illustrating the need for more guidance targeted for GPs. Besides, all guidelines to some extent provided recommendations that were opinion based, reflecting the need of more high quality studies on cancer recurrence risk management.
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